Novartis To Test Novel Launch Strategy For Cholesterol Drug Leqvio

To Avoid The Fate Of Pcsk9 Inhibitors Repatha (Evocolumab) And Praluent (Alirocumab), Which Have Muddled Through Underwhelming Launches In Recent Years, Novartis Pharmaceuticals President Marie-France Tschudin Said The Company Plans To Work Directly With The Top 200 Hospital Systems In The Us To Identify Patients Who Would Be Most Likely To Benefit From Leqvio (Inclisiran). Time Will Tell Whether Its Launch Strategy Will Translate Into Improved Uptake Versus The Pcsk9 Drugs That Came Before It. What HappenedThe Fda Approved Leqvio, A Pcsk9-Targeting Sirna Therapy, To Lower Ldl Cholesterol. Leqvio Is Administered Twice Per Year After Two Initial Doses Within The First Three Months Of Treatment. Novartis Plans To Launch The Drug In Early January 2022 At $3,250 Per Dose, Which Would Be $9,750 The First Year And $6,500 In Subsequent Years. The BackstoryWhile The Fda Issued A Complete Response Letter For Leqvio In December 2020, Citing An Inspection Issue At A Third-Party Manufacturing Facility, Analysts And Physicians Largely Believe The Molecule Could Change The Way High Cholesterol Is Treated Given The Convenience Of Its Twice-Yearly Dosing Profile. Many Analysts Think Novartis Overpaid To Acquire Leqvio

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!